Back to Search
Start Over
Antibody-drug conjugates targeting prostate-specific membrane antigen.
- Source :
-
Frontiers in bioscience (Landmark edition) [Front Biosci (Landmark Ed)] 2014 Jan 01; Vol. 19 (1), pp. 12-33. Date of Electronic Publication: 2014 Jan 01. - Publication Year :
- 2014
-
Abstract
- Prostate-specific membrane antigen (PSMA) is an integral, non-shed membrane glycoprotein that is a well-characterized and clinically validated marker of prostate cancer. The expression profile and other biological properties of PSMA make it an attractive target for antibody-drug conjugate (ADC) therapy of prostate cancer, as well as a broad range of other tumors in which PSMA is abundantly expressed within the tumor neovasculature. PSMA-targeted ADCs have been developed using auristatin and maytansinoid drugs, and each ADC has undergone extensive preclinical testing and has completed phase 1 testing in men with advanced prostate cancer. The preclinical and clinical findings have largely substantiated the promise of PSMA as an ADC target. This report summarizes the completed studies, current status, and potential future directions for ADCs that target PSMA.
- Subjects :
- Antigens, Surface immunology
Glutamate Carboxypeptidase II immunology
Humans
Immunoconjugates adverse effects
Immunoconjugates pharmacology
Male
Prostatic Neoplasms therapy
Antigens, Surface drug effects
Glutamate Carboxypeptidase II drug effects
Immunoconjugates therapeutic use
Prostatic Neoplasms immunology
Subjects
Details
- Language :
- English
- ISSN :
- 2768-6698
- Volume :
- 19
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Frontiers in bioscience (Landmark edition)
- Publication Type :
- Academic Journal
- Accession number :
- 24389170
- Full Text :
- https://doi.org/10.2741/4193